A Comprehensive Review on Sodium Glucose Co-Transporter-2 Inhibitors-Empagliflozin

Arun, Sanjaana; Praveen, D.; P, Ranadheer Chowdary; M, Vijey Aanandhi

doi:10.52711/0974-360x.2022.00395

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This results in an increase in the excretion of glucose through urine [ 22 ]. Empagliflozin is a suitable treatment option for patients with type 2 diabetes mellitus due to its high-capacity transport of glucose protein and low affinity to plasma proteins [ 23 ]. Additionally, the use of Empagliflozin has been associated with various benefits in heart function and cardiovascular problems such as heart failure, regardless of glucose tolerance status [ 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial

Zandifar,

Panahi,

Badrfam

et al. 2024

BMC Psychiatry

View full text Add to dashboard Cite

Background Major depressive disorder is one of the most common psychiatric disorders, which is associated with a high disease burden. Current treatments using antidepressants have limitations, so using medication with neuromodulating and anti-inflammatory properties alongside them could be helpful. In a clinical trial, we studied the effectiveness of empagliflozin, a blood sugar-lowering drug, as an adjunctive therapy to reduce the severity of depression symptoms. Methods A number of outpatients with moderate to severe depression (Hamilton Depression Rating Scale (HDRS) > = 17) who were not under related medication or had not taken medication for at least the last two months, had an age range of 18–60 years and had written informed consent to enter the study (N = 90) were randomly divided into two groups receiving placebo or empagliflozin (10 mg daily) combined with citalopram (40 mg daily) based on permuted block randomization method in an 8-week randomized, double-blind, placebo-controlled clinical trial. They were evaluated using the HDRS in weeks 0, 4, and 8. Results HDRS scores were equal to 28.42(± 3.83), 20.20(± 3.82), and 13.42(± 3.42) in the placebo group during weeks 0,4, and 8, respectively. These scores were 27.36(± 3.77), 13.76(± 1.40), and 7.00(± 1.13), respectively, for the group treated with empagliflozin. Compared to the control group, patients treated with empagliflozin using repeated-measures ANOVA showed greater improvement in reducing the severity of depression symptoms over time (p value = 0.0001). Conclusions Considering the promising findings in this clinical trial, further study of empagliflozin as adjunctive therapy in MDD with larger sample sizes and longer follow-ups is recommended.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial

Zandifar,

Panahi,

Badrfam

et al. 2024

BMC Psychiatry

View full text Add to dashboard Cite

show abstract

Effects of empagliflozin on a model of chronic depression and brain Toll-like receptors gene expression in male rats

Al-Charrakh,

Mijwel,

Salman

2023

Med J Babylon

View full text Add to dashboard Cite

Human Organic Cation Transporter Use and Drug Target Responses

Navya Sai,

Abdul Ahad,

Chinthaginjala

et al. 2023

AJRC

View full text Add to dashboard Cite

The goal of the current work was to explore the human organic cation uptake transporter and its critical function in biological transportation. The hOCT is extensively articulated in the liver and has been found to have a broad range of substrate selectivity, which is encoded by the SLC22A1 gene. OCT1 promotes molecular diffusion, enabling nutrients to enter the cell. OCT1 can aid in the absorption of drugs used to treat illnesses like cancer, according to recent research. Functionally impaired OCT1, whose appearance levels are associated with responses to a variety of medications, is the root cause of drug resistance. One of the important pharmacological targets employed in pharmacogenomic studies has recently been proposed as OCT1. The entire OCT1 gene contains a few single nucleotide polymorphisms. Also unknown are the specific changes or interactions with other proteins required for OCT1 to recognize a range of ligands. The authors presented the most recent OCT1 findings in this review to stimulate further investigation into this crucial uptake transporter.

show abstract

A Comprehensive Review on Sodium Glucose Co-Transporter-2 Inhibitors-Empagliflozin

Cited by 3 publications

References 11 publications

Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial

Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial

Effects of empagliflozin on a model of chronic depression and brain Toll-like receptors gene expression in male rats

Human Organic Cation Transporter Use and Drug Target Responses

Contact Info

Product

Resources

About